Pharmalittle: We're reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more

AstraZeneca has launched a three-year cost-cutting program that aims to slice off $1.5 billion a year, with the savings reinvested in R&D

Continue in Briflio to read, react, comment, and share.